AVZO-021-1001: A first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors

被引：0
|
作者：
Dowlati, A. [1 ]
Richardson, D. L. [2 ]
Lorusso, P. [3 ]
Spira, A. I. [4 ]
Bashir, B. [5 ]
Hirmand, M. [6 ]
Mehta, M. [6 ]
Patel, M. R. [7 ]
机构：
[1] Case Western Reserve Univ, Div Hematol & Oncol, Dept Med, Cleveland, OH USA
[2] Univ Oklahoma, Gynecol Oncol Sect, Dept Obstet & Gynecol Sect Gynecol Oncol, Stephenson Canc Ctr, Oklahoma City, OK USA
[3] Yale Univ, Dept Med Oncol, Yale Comprehens Canc Ctr, Sch Med, New Haven, CT USA
[4] Virginia Canc Specialists, VCS Res Inst, Fairfax, VA USA
[5] Thomas Jefferson Univ, Div Solid Tumors, Dept Med Oncol, Sidney Kimmel Canc Ctr, Philadelphia, PA USA
[6] Avenzo Therapeut Inc, Clin Dev, San Diego, CA USA
[7] Florida Canc Specialists, Drug Dev Unit, Sarasota, FL USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.386
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
439TiP
引用
收藏
页码：S405 / S405
页数：1
相关论文
共 50 条
  • [11] A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors
    Yu, X.
    Zhang, J.
    Liu, R.
    Deng, Y.
    Cai, Y.
    Sun, Y.
    Dang, Q.
    Hong, W.
    Song, Z.
    Guo, S.
    Gao, S.
    Su, W.
    Shi, M.
    Fan, S.
    Zhang, B.
    Pan, B.
    Ren, Y.
    Wang, J.
    Zhong, C.
    Ma, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1496 - S1497
  • [12] A phase I/II, open-label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI-999 in patients with advanced solid tumors.
    Tsimberidou, Apostolia Maria
    Ajani, Jaffer A.
    Hsu, Pei
    Chen, I-Ju
    Pearce, Tillman E.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [13] A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
    Duca, Matteo
    Lim, Darren Wan-Teck
    Subbiah, Vivek
    Takahashi, Shunji
    Sarantopoulos, John
    Varga, Andrea
    D'Alessio, Joseph A.
    Abrams, Tinya
    Sheng, Qing
    Tan, Eugene Youchin
    Rosa, Maria Santos
    Gonzalez-Maffe, Juan
    Sand-Dejmek, Janna
    Fabre, Claire
    Martin, Miguel
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (04) : 625 - 634
  • [14] A phase I/II multicenter, open-label, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study of Q901 administered via intravenous infusion in adult patients with selected advanced solid tumors with a cohort expansion at the recommended phase II dose
    Alistar, A.
    Mahalingam, D.
    Barve, M.
    Borad, M.
    Babiker, H.
    Xie, H.
    Choi, B.
    Ahn, J.
    Choi, J.
    Ahn, K.
    Ryu, S.
    Kim, J.
    Yu, D.
    Lee, S-J.
    Jeon, B.
    Proniuk, S.
    Kim, J.
    Nam, K.
    El-Khoueiry, A. B.
    ANNALS OF ONCOLOGY, 2023, 34 : S492 - S492
  • [15] First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
    Tianhong Li
    Patricia LoRusso
    Michael L. Maitland
    Sai-Hong Ignatius Ou
    Erkut Bahceci
    Howard A. Ball
    Jung Wook Park
    Geoffrey Yuen
    Anthony Tolcher
    Journal of Hematology & Oncology, 9
  • [16] First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
    Li, Tianhong
    LoRusso, Patricia
    Maitland, Michael L.
    Ou, Sai-Hong Ignatius
    Bahceci, Erkut
    Ball, Howard A.
    Park, Jung Wook
    Yuen, Geoffrey
    Tolcher, Anthony
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [17] A phase I, first-in-human, dose-escalation and dose expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Wan, Qunfang
    Xiong, Wendy
    Peng, Peng
    Yang, Xiaoju
    Wu, Henry
    Ngo, Brenda
    Wu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [18] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
    Bendell, Johanna C.
    Patel, Manish R.
    Moore, Kathleen N.
    Chua, Cynthia C.
    Arkenau, Hendrik-Tobias
    Dukart, Gary
    Harrow, Kim
    Liang, Chris
    ONCOLOGIST, 2019, 24 (04): : 455 - E121
  • [19] Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
    Reid, Tony
    Oronsky, Bryan
    Scicinski, Jan
    Scribner, Curt L.
    Knox, Susan J.
    Ning, Shoucheng
    Peehl, Donna M.
    Korn, Ron
    Stirn, Meaghan
    Carter, Corey A.
    Oronsky, Arnold
    Taylor, Michael J.
    Fitch, William L.
    Cabrales, Pedro
    Kim, Michelle M.
    Burris, Howard A.
    Lao, Christopher D.
    Abrouk, Nacer E. D.
    Fanger, Gary R.
    Infante, Jeffrey R.
    LANCET ONCOLOGY, 2015, 16 (09): : 1133 - 1142
  • [20] A first-in-human phase Ia/b, open-label, multicentre, dose-escalation study of BI 905711 in patients with advanced gastrointestinal cancers
    Harding, J.
    Hofheinz, R.
    Elez, E.
    Kuboki, Y.
    Geng, J.
    Schmohl, M.
    Dowling, E.
    Feng, Y.
    Rasco, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S145 - S145
12345